Question ledger — Synthetic Biology

Observed: 2026-07-23
Last updated: 2026-07-23
Status: stabilized after multi-source research round (web + X + prior longevity package cross-read)

Primary questions (12)

P1. What is synthetic biology as an EmTech, and how does it sit between bits and atoms?

• S1.1 How does gene sequencing turn atoms (cells) into bits (digital sequences)?
• S1.2 How does gene editing / synthesis turn bits back into atoms (living systems)?
• S1.3 How does this differ from classical genetic engineering and from pure biotech drugs?
• S1.4 Which fixed OOM EmTech nodes does it decompose into (Gene Sequencing, Genetic Engineering, Alternative Proteins)?
• S1.5 What is the Core Mechanism that makes the whole stack cohere?
• S1.6 Is synthetic biology itself an LAC or a platform EmTech that unlocks many LACs?
• S1.7 Where is strong vs weak convergence with AI, robotics, 3D printing, and energy?

P2. What are DNA, genes, and proteins — in hard-to-vary mechanistic language?

• S2.1 What is a base pair, a codon, a gene, a genome, a chromosome?
• S2.2 How does transcription and translation actually work (central dogma)?
• S2.3 What do proteins do that makes life run?
• S2.4 Why does digitalizing this stack create exponential tool improvement?
• S2.5 How does epigenetics fit without abandoning the DNA-as-code metaphor?
• S2.6 What would falsify the “life is programmable information” framing?

P3. What can gene sequencing do today, and how fast did cost/throughput compound?

• S3.1 Human Genome Project cost and timeline vs NovaSeq-class $200 genome claims
• S3.2 Metric, rate, mechanism, bottlenecks (Trend-analysis Rule)
• S3.3 Clinical vs research vs consumer sequencing
• S3.4 Long-read vs short-read; single-cell and multi-omics
• S3.5 What new applications unlock below $100 / $10 / $1 effective genome economics?
• S3.6 Who controls the instrument stack (Illumina and challengers)?

P4. What can gene editing do today, and what milestones matter?

• S4.1 CRISPR-Cas9 mechanism vs base editors vs prime editors
• S4.2 Casgevy (exa-cel) as first approved CRISPR medicine (2023)
• S4.3 Delivery problem (AAV, LNPs, ex vivo HSCs)
• S4.4 Multiplex editing at scale (pigs, mice, wolves)
• S4.5 Off-target risk, mosaic edits, germline ethics
• S4.6 Path from rare monogenic disease to common complex disease

P5. Have humans created full synthetic life forms — and what does that claim mean?

• S5.1 JCVI-syn1.0 (2010) vs syn3.0 (2016) minimal cell
• S5.2 Chemically synthesized genome vs de novo designed organism
• S5.3 Unknown essential genes problem (~149 of unknown function in syn3.0)
• S5.4 Bottom-up synthetic cells / protocells status
• S5.5 Mirror life and other extreme risk framings
• S5.6 What milestone would count as “designed life from a blank CAD file”?

P6. What has Colossal Biosciences actually done on de-extinction?

• S6.1 Dire wolf claim (2024–2025 births) vs scientific consensus on “not true dire wolves”
• S6.2 Method: ancient DNA → trait edits on gray wolf / related canid
• S6.3 Woolly mouse, mammoth edit list, elephant surrogate / gestation path
• S6.4 Pipeline: dodo, thylacine, moa, bluebuck
• S6.5 Conservation gym thesis vs spectacle/PR thesis
• S6.6 Valuation/funding signal quality (treat secondary capital rumors carefully)
• S6.7 Ecological release barriers and welfare ethics

P7. How is United Therapeutics turning gene-edited pigs into transplantable organs?

• S7.1 UKidney 10-gene-edit design (KO + human gene add)
• S7.2 FDA IND clearance (Feb 2025) and first EXPAND trial transplant (Nov 2025, NYU Langone)
• S7.3 eGenesis parallel path
• S7.4 UHeart and lung pipeline
• S7.5 Rejection, zoonosis (PERV), growth control, immunosuppression
• S7.6 Time-to-BLA and decade-scale access realism
• S7.7 How this differs from bioprinted organs and human organoids

P8. What is real vs hype in longevity research through a synthetic-biology lens?

• S8.1 Hallmarks of aging and measurable biological age (epigenetic clocks)
• S8.2 Partial epigenetic reprogramming (OSK/OSKM) mechanism
• S8.3 Life Biosciences ER-100 FDA clearance (Jan 2026) and disease-specific path
• S8.4 LEV claim quality by 2030 (cross-ref prior longevity package)
• S8.5 Senolytics, gene therapy for aging, cell therapy
• S8.6 Delivery, cancer risk, and regulatory “treat a disease first” strategy

P9. Can alternative proteins feed people at scale without conventional livestock?

• S9.1 Precision fermentation vs cultivated meat vs plant-based
• S9.2 Cost curves, regulatory approvals, sensory parity
• S9.3 Energy and feedstock intensity
• S9.4 Who is winning commercially vs who is stuck in pilot hell?
• S9.5 Synbio’s role (strain engineering, growth factors, serum-free media)
• S9.6 Contrarian: land-use rebound, cultural resistance, “lab food” politics

P10. Is vertical farming a real food pathway or a capital destruction story?

• S10.1 Unit economics: energy share of COGS (lighting ~50–65%)
• S10.2 2023–2025 bankruptcies and funding winter; 2026 survivor cohort
• S10.3 Crop envelope (leafy greens vs staples)
• S10.4 Convergence with LEDs, renewables, robotics, AI climate control
• S10.5 Where CEA wins (deserts, cities, high-value fresh) and where it loses
• S10.6 Link to synbio (optimized cultivars for indoor light recipes)

P11. What are the governing trends, bottlenecks, and 5–15 year predictions?

• S11.1 Sequencing cost curve classification
• S11.2 Design-build-test cycle time with AI protein/genome models
• S11.3 Clinical gene editing expansion
• S11.4 Organ scarcity resolution path
• S11.5 Food: alt-protein + CEA + breeding stack
• S11.6 What would falsify the “biology century” narrative?

P12. What are the strongest contrarian critiques and failure modes?

• S12.1 Overclaiming de-extinction and synthetic life
• S12.2 Biosecurity (DNA synthesis screening, dual use)
• S12.3 Inequality of access (million-dollar CRISPR cures)
• S12.4 Ecological risk of engineered organisms
• S12.5 Energy wall for indoor biology and food
• S12.6 Regulatory fragmentation and public trust

Rabbit holes opened and disposition

RH	Trigger	Disposition
RH1	Dire wolf “de-extinction” language vs IUCN/canid specialists	Integrated in ch.05 — proxies not species resurrection
RH2	Unknown genes in minimal cell	Integrated in ch.04 — design still partly empirical
RH3	Xenotransplant trial design “phaseless” BLA path	Integrated in ch.06
RH4	Vertical farm energy standing-charge shocks (UK 2026)	Integrated in ch.09
RH5	Life Bio ER-100 is optic neuropathy, not systemic de-aging	Integrated in ch.07 — critical for hype control
RH6	AI protein design as strong convergence	Integrated in ch.03/10

Unresolved (explicit)

• U1: Exact multiplex edit count and genome composition for Colossal dire wolf pups (company narrative vs independent sequencing papers) — treat as partially disclosed.
• U2: Long-term graft survival and zoonotic safety endpoints for EXPAND UKidney — trial ongoing as of research date.
• U3: Whether Life Biosciences first-in-human dosing has public efficacy data beyond IND clearance / early dosing signals — track primary releases.
• U4: True all-in cost of clinical-grade whole genome (not list-price $200 reagent marketing).
• U5: Commercial path to commodity cultivated meat at supermarket parity prices in major markets.

Saturation note

Primaries P1–P12 answered with multi-source evidence; contrarian scan completed for Colossal, CEA, longevity hype, and xenotransplant timelines. Further rounds should be delta-only (trial readouts, mammoth embryo claims, sequencing price cards).